Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06471829 · ClinicalTrials.gov registry record · Phase 2

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

A Phase 2 study of Cushing's Disease, sponsored by H. Lundbeck A/S.

Recruiting
Registry status
Phase 2
Development phase
18
Enrollment target
20
Study locations

NCT06471829: Recruiting Phase 2 study of Cushing's Disease, sponsored by H. Lundbeck A/S.

NCT06471829 is a Phase 2 study of Cushing's Disease that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 18 participants, below the 128-participant average among 5 other Cushing's Disease trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06471829, a Phase 2 study of Cushing's Disease, is actively recruiting participants, sponsored by H. Lundbeck A/S.

RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
20
Study locations

Study Summary

This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).

Conditions Studied

Cushing's Disease

Interventions

  • DRUG Lu AG13909

Study Locations (20)

Other

  • Hopital Louis Pradel - Bron
  • APHP - Hôpital Bicêtre - Le Kremlin-Bicêtre
  • Centre Hospitalier Universitaire De Lille - Lille
  • Hopital Haut-Leveque - Pessac
  • Ltd Aversi Clinic - Tbilisi
  • Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika - Budapest
  • Debreceni Egyetem Klinikai Kozpont - Debrecen
  • University Hospital of Pecs - Pécs
  • AOU Policlinico G. Martino - Messina
  • Azienda Ospedaliera Universitaria Sant'Andrea - Rome
  • AOU Citta della Salute e della Scienza di Torino - Torino
  • Institutul National de Endocrinologie "C.I. Parhon" - Bucharest

Europe

  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital La Conception - Marseille
  • Ltd Tbilisi Central Hospital - Tbilisi
  • National Institute of Endocrinology - Tbilisi
  • Multiprofile Clinic Consilium Medulla Ltd - Tbilisi
  • Azienda Ospedale Università di Padova - Padua
  • Azienda Ospedaliero-Universitaria Pisana - Pisa

Michigan

  • University of Michigan - Ann Arbor

Cedex 09

  • Centre Hospitalier Universitaire d'Angers - Angers

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2024-06-19
Est. Completion 2027-11-30
Phase Phase 2
H. Lundbeck A/S

72 total trials

What NCT06471829 shows while recruiting

NCT06471829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 128-participant average among 5 other Cushing's Disease trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Cushing's Disease appearing as the primary indexed condition, and to 1 intervention - of which Lu AG13909 is the first listed.

NCT06471829 names 20 study sites across 4 states, led by Other, Europe, Michigan.

Frequently Asked Questions

What is clinical trial NCT06471829 about?

NCT06471829 is a clinical study titled "A Trial of Lu AG13909 in Adult Participants With Cushing's Disease". This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the ...

What is the current status of trial NCT06471829?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-06-19. Estimated completion is 2027-11-30.

What conditions does trial NCT06471829 study?

This clinical trial studies the following conditions: Cushing's Disease.

What interventions are being tested in trial NCT06471829?

The interventions under investigation include: Lu AG13909 (DRUG).

Who is sponsoring clinical trial NCT06471829?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06471829 being conducted?

This trial has 20 study locations across Michigan, Cedex 09, Europe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cushing's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06471829

Source: ClinicalTrials.gov NCT06471829, the US trial registry maintained by the National Library of Medicine. NCT06471829 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.